Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome)

363  relevant articles (21 outcomes, 16 trials/studies) found for this Disease

Lambert-Eaton Syndrome; Eaton Lambert Syndrome; Syndrome, Lambert-Eaton; Syndrome, Lambert-Eaton Myasthenic; Eaton-Lambert Myasthenic Syndrome; Myasthenic-Myopathic Syndrome of Eaton-Lambert; Myasthenic-Myopathic Syndrome of Lambert-Eaton; Myopathic-Myasthenic Syndrome of Eaton-Lambert; Myopathic-Myasthenic Syndrome of Lambert-Eaton; Eaton Lambert Myasthenic Syndrome; Eaton-Lambert Myasthenic-Myopathic Syndrome; Eaton-Lambert Myopathic-Myasthenic Syndrome; Eaton-Lambert Myopathic-Myasthenic Syndromes; Lambert Eaton Myasthenic Syndrome; Lambert Eaton Syndrome; Lambert-Eaton Myasthenic-Myopathic Syndrome; Lambert-Eaton Myasthenic-Myopathic Syndromes; Lambert-Eaton Myopathic-Myasthenic Syndrome; Lambert-Eaton Myopathic-Myasthenic Syndromes; Myasthenic Myopathic Syndrome of Eaton Lambert; Myasthenic Myopathic Syndrome of Lambert Eaton; Myasthenic Syndrome, Eaton-Lambert; Myasthenic Syndrome, Lambert Eaton; Myopathic Myasthenic Syndrome of Eaton Lambert; Syndrome, Eaton-Lambert; Syndrome, Eaton-Lambert Myasthenic; Eaton-Lambert Syndrome; Myasthenic Syndrome, Lambert-Eaton

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Syndrome
2.	Dermatomyositis (Dermatopolymyositis)
3.	Polyneuropathies (Polyneuropathy)
4.	Stiff-Person Syndrome (Stiff Man Syndrome)
5.	Myasthenia Gravis

Experts

1.	Lang, Bethan: 4 articles (07/2005 - 05/2002)
2.	Vincent, Angela: 3 articles (09/2008 - 09/2003)
3.	Newsom-Davis, John: 3 articles (09/2003 - 05/2002)
4.	Komai, K: 3 articles (04/2000 - 02/2000)
5.	Takamori, M: 3 articles (04/2000 - 02/2000)
6.	Takamori, Masaharu: 2 articles (09/2008 - 10/2004)
7.	Martin-Moutot, Nicole: 2 articles (06/2008 - 04/2006)
8.	Seagar, Michael: 2 articles (06/2008 - 04/2006)
9.	Sanadze, A G: 2 articles (02/2007 - 01/2006)
10.	Shcherbakova, N I: 2 articles (02/2007 - 01/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lambert-Eaton Myasthenic Syndrome:

1.	3,4-diaminopyridineIBA 09/01/1998 - "3,4-Diaminopyridine (3,4-DAP) is known to be beneficial in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). " 12/07/1989 - "We conclude that 3,4-diaminopyridine, either alone or in conjunction with other therapies, may be useful in the treatment of Lambert-Eaton myasthenic syndrome." 11/01/2009 - "The purpose of this study was to investigate the clinical and electrophysiological efficacy of 3,4-diaminopyridine (DAP) in patients with Lambert-Eaton myasthenic syndrome (LEMS) in a randomized, double-blind, cross-over drug trial. " 08/01/1998 - "Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome." 01/01/2005 - "MAIN RESULTS: Two controlled trials of the effects of 3,4-diaminopyridine compared with placebo in a total of 38 patients with Lambert-Eaton myasthenic syndrome were eligible, one of which was of crossover design. " Order ALL the reference details at left...
2.	Intravenous Immunoglobulins (IVIG)FDA Link 05/01/2005 - "Lambert-Eaton myasthenic syndrome: A placebo-controlled crossover study reported a significant clinical improvement in the amplitude of the resting CMAP following IVIg treatment. " 08/01/1996 - "Lambert-Eaton (myasthenic) syndrome: pre-anaesthetic treatment with intravenous immunoglobulins." 09/01/2006 - "According to the response to IVIG therapy, paraneoplastic disorders may be subgrouped in group A, a clinical response is the rule (prototype Lambert-Eaton myasthenic syndrome), and in group B, IVIG may be helpful in single patients and is indicated in specific clinical settings (prototype anti-Hu associated neurological syndromes). " 08/01/2008 - "RESULTS/CONCLUSION: There are small randomised controlled trials that demonstrate the efficacy of IVIg in dermatomyositis, myasthenic crisis, Lambert-Eaton myasthenic syndrome and stiff-person syndrome. " 05/01/2005 - "IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status." Order ALL the reference details at left...
3.	Immunoglobulins (Immunoglobulin)IBA 01/01/2003 - "A third crossover trial compared intravenous immunoglobulin treatment to placebo in nine patients with Lambert-Eaton myasthenic syndrome. " 12/01/2002 - "Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome." 06/01/1997 - "Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin." 05/01/1997 - "Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin." 02/01/1994 - "[Response to combined therapy with plasmapheresis and high doses of immunoglobulin in Lambert-Eaton syndrome]" Order ALL the reference details at left...
4.	Guanidine (Guanidine Nitrate)FDA Link 09/01/1997 - "Guanidine hydrochloride is known to be highly effective in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). " 10/01/1977 - "Eaton-Lambert syndrome: reflex improvement with guanidine." 01/14/1978 - "[A further case of Lambert-Eaton syndrome: remarkable action of guanidine]" 04/09/1977 - "Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome." 10/01/1973 - "Guanidine hydrochloride in the Eaton-Lambert syndrome. " Order ALL the reference details at left...
5.	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 10/01/2009 - "Pyridostigmine seems not to have an additional effect to 3-4 diaminopyridine in Lambert Eaton myasthenic syndrome. " 07/01/2007 - "[Treatment of Lambert-Eaton syndrome with 3,4- diaminopyridine and pyridostigmine]" 09/01/1997 - "Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome." 07/01/2009 - "Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study." 07/01/2009 - "3,4-Diaminopyridine and pyridostigmine are widely used to treat Lambert-Eaton myasthenic syndrome (LEMS), either alone or in combination. " Order ALL the reference details at left...
6.	AntibodiesIBA 09/10/2009 - "We validated an enzyme-linked immunosorbent assay (ELISA) to assess the diagnostic value of serum antibodies in SCLC and Lambert-Eaton myasthenic syndrome (LEMS). " 03/18/2008 - "SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome." 05/13/1998 - "Specificity of the Lambert-Eaton syndrome antibodies. " 01/01/1998 - "Our results suggest that this experimental model is different from that of Lambert-Eaton myasthenic syndrome and that antibodies to PsmR may also be involved in the pathogenesis of MG." 08/01/1997 - "Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse." Order ALL the reference details at left...
7.	Immunoglobulin M (IgM)IBA 05/01/1997 - "In other controlled or open-label trials and case reports, IVIg produced improvement in several patients with the Lambert-Eaton myasthenic syndrome and myasthenia gravis but had a variable, mild, or unsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinating polyneuropathy, certain intractable childhood epilepsies, polymyositis, multiple sclerosis, optic neuritis, and the stiff-man syndrome. " 04/01/2007 - "Recommendations for use of IVIG were made for 14 conditions, including acute disseminated encephalomyelitis, chronic inflammatory demyelinating polyneuropathy, dermatomyositis, diabetic neuropathy, Guillain-Barré syndrome, Lambert-Eaton myasthenic syndrome, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, opsoclonus-myoclonus, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, polymyositis, Rasmussen's encephalitis, and stiff person syndrome; IVIG was not recommended for 8 conditions including adrenoleukodystrophy, amyotropic lateral sclerosis, autism, critical illness polyneuropathy, inclusion body, myositis, intractable childhood epilepsy, paraproteinemic neuropathy (IgM variant), and POEMS syndrome. " 05/01/1995 - "The neurological diseases with definite or putative immune pathogenesis include myasthenia gravis; Lambert-Eaton myasthenic syndrome; IgM monoclonal anti-myelin-associated glycoprotein-associated demyelinating polyneuropathy; Guillain-Barré syndrome; chronic inflammatory demyelinating polyneuropathy; multifocal motor neuropathy with or without GM1 antibodies; multiple sclerosis; inflammatory myopathies; stiff-man syndrome; autoimmune neuromyotonia; paraneoplastic neuronopathies and cerebellar degeneration; and neurological diseases associated with systemic autoimmune conditions, vasculitis, or viral infections. " 11/01/1994 - "These are; ple21 in limbic encephalitis; PCD17, CDR62, CDR34, and CZF in paraneoplastic cerebellar degeneration; one of the anion transporters band 3 in chorea-acanthocytosis; visinin-like substance in cancer-associated retinopathy (CAR syndrome); myelin basic protein (MBP) and proteolipid protein (PLP) in acute disseminated encephalomyelitis; MBP, PLP and myelin-oligodendrocyte glycoprotein (MOG) in multiple sclerosis; glutamic acid decarboxylase in stiff-man syndrome; GM1 ganglioside in amyotrophic lateral sclerosis; peripheral nerve K+ channel in Isaacs syndrome; synaptotagmin in Lambert-Eaton syndrome; acetylcholine receptor in myasthenia gravis; GM1 ganglioside in Guillain-Barré syndrome; GQ1b ganglioside in Fisher syndrome; myelin-associated glycoprotein in IgM paraproteinemic neuropathy; HuD in paraneoplastic sensory neuropathy; and tRNA and HSP65 in polymyositis." Order ALL the reference details at left...
8.	AutoantibodiesIBA 01/01/1997 - "Some disorders, such as the Lambert-Eaton myasthenic syndrome, are effectively treated by removal of autoantibodies directed against the presynaptic cholinergic synapse. " 09/01/2003 - "Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome." 04/01/1999 - "wt 58,000) are general targets of Lambert-Eaton myasthenic syndrome autoantibodies. " 05/13/1998 - "The role of autoantibodies in Lambert-Eaton myasthenic syndrome." 01/01/1995 - "The autoantibodies implicated in the Lambert-Eaton myasthenic syndrome (LES), which are known to inhibit ICa and INa in bovine adrenal chromaffin cells, also significantly inhibited INa in SCLC cells. " Order ALL the reference details at left...
9.	Immunoglobulin G (IgG)IBA 04/01/1999 - "The immunoglobulin G fractions from Lambert-Eaton myasthenic syndrome patients immunoprecipitate solubilized neuronal N- and P/Q-type channels and in certain cases brain, skeletal and cardiac muscle L-type channels [El Far O. " 11/01/1996 - "Incubation of cells with Lambert-Eaton myasthenic syndrome IgG for 24 to 48 hours removed up to 71% of the whole-cell current. " 08/15/1995 - "1. The effects of immunoglobulin G (IgG) from patients with Lambert-Eaton myasthenic syndrome on Ca2+ currents in mammalian motor nerve terminals are unknown. " 03/03/1995 - "The immunochemical and functional properties of IgG fractions from patients with Lambert-Eaton myasthenic syndrome (LEMS) were examined in chick and rat synaptosomes. " 08/01/1989 - "The best evidence for this hypothesis is found in the Lambert-Eaton myasthenic syndrome which can be transferred to animals by injecting them with IgG from patients. " Order ALL the reference details at left...
10.	Prednisolone (Predate)FDA LinkGeneric 08/01/1984 - "A 34-year-old women with the Eaton-Lambert myasthenic syndrome was treated with prednisolone for over a year. " 08/01/1984 - "The Eaton-Lambert myasthenic syndrome and long-term treatment with prednisolone." 11/01/1999 - "Lambert-Eaton myasthenic syndrome associated with idiopathic thrombocytopenic purpura and diffuse panbronchiolitis: long-term remission after a course of intravenous immunoglobulin combined with low-dose prednisolone." 04/01/1984 - "We undertook serial clinical and electromyographic muscle action potential (MAP) amplitude assessments in nine patients with the Lambert-Eaton myasthenic syndrome (LEMS) over 0.5 to 2.5 years who received plasma exchange (PE; 5 to 15 exchanges over 4 to 19 days) and immunosuppressive drug (IS) treatment (prednisolone 60 to 100 mg on alternate days, azathioprine 2.5 mg/kg for 0.5 to 2.5 years), and who had no signs of carcinoma at entry. " 01/01/2003 - "A 74 year-old Japanese woman, who had suffered from Lambert-Eaton myasthenic syndrome (LEMS), Sjoegren's syndrome, and discoid lupus erythematosus for 10 years and had been successfully controlled by 3,4-diaminopyridine and prednisolone, began to suffer from chest discomfort at night. " Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/01/2006 - "Chemotherapy has successfully ameliorated the course of disease in Lambert-Eaton myasthenic syndrome patients with an underlying tumour." 03/01/1994 - "Lambert-Eaton myasthenic syndrome: evaluation of movement performance following drug therapy." 01/01/1979 - "Eaton-Lambert syndrome: electrophysiological normalization during chemotherapy." 06/01/1982 - "Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome." 01/01/1982 - "To our knowledge, it has not been reported before that chemotherapy alone of a small cell bronchogenic carcinoma has resulted in clinical, roentgenologic, and electrophysiologic remission of the Eaton-Lambert syndrome." Order ALL the reference details at left...
2.	Plasma Exchange 04/01/1984 - "Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome." 08/01/1981 - "The myasthenic (Eaton-Lambert) syndrome, associated with carcinoma of the bronchus in one patient and with immunological disorders in two others, improved after plasma exchange--observations supported by electromyographic evidence in two cases. " 07/01/2006 - "Although widely used, the potential benefit of plasma exchange in the treatment of multiple sclerosis, myasthenia gravis, and Lambert-Eaton syndrome is less clear." 08/01/1984 - "Treatment with plasma exchange, steroids, immunosuppressant drugs and cytotoxic chemotherapy was effective in two cases of cancer-associated Eaton-Lambert myasthenic syndrome. " 04/01/1984 - "We undertook serial clinical and electromyographic muscle action potential (MAP) amplitude assessments in nine patients with the Lambert-Eaton myasthenic syndrome (LEMS) over 0.5 to 2.5 years who received plasma exchange (PE; 5 to 15 exchanges over 4 to 19 days) and immunosuppressive drug (IS) treatment (prednisolone 60 to 100 mg on alternate days, azathioprine 2.5 mg/kg for 0.5 to 2.5 years), and who had no signs of carcinoma at entry. " Order ALL the reference details at left...
3.	Electrodes (Electrode) 10/01/1976 - "The diagnosis of Eaton-Lambert syndrome was confirmed by clinical neurophysiologic studies and by intracellular electrode studies of end-plate potentials from an intercostal muscle biopsy. " Order ALL the reference details at left...
4.	Plasmapheresis 06/01/1982 - "Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome." 08/01/2006 - "Myasthenia gravis and Lambert-Eaton syndrome represent neuromuscular disorders where plasmapheresis might be of potential efficacy." 02/01/1994 - "[Response to combined therapy with plasmapheresis and high doses of immunoglobulin in Lambert-Eaton syndrome]" 10/01/1990 - "Eleven patients had plasmapheresis; 6 patients with the Guillain-Barré syndrome, and patients with thrombotic thrombocytopenic purpura (TTP), Eaton-Lambert syndrome, myasthenia gravis, post transfusion purpura, and multiple myeloma complicated by hyperviscosity and coagulopathy. " 06/01/1982 - "Five patients with Eaton-Lambert syndrome (ELS) without associated malignancy were first treated by plasmapheresis alone, and subsequently by plasmapheresis combined with prednisone and azathioprine therapy. " Order ALL the reference details at left...
5.	Injections 02/01/1985 - "Mice were given 1 to 67 daily injections of whole plasma from a control subject and a patient with the Lambert-Eaton myasthenic syndrome (LES), and the parameters of neuromuscular transmission in diaphragm muscles were studied in vitro. " 11/01/1993 - "Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome." Order ALL the reference details at left...